Products | Oncology Diagnostics | September 18, 2015

EMI-137

EMI-137

Related Content

LUMISIGHT and Lumicell Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from second surgeries
News | FDA
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
Ga-68 has a very short half-life, which presents logistical challenges in distribution
News | Radiopharmaceuticals and Tracers
RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
With the addition of MIM Software, GE HealthCare aims to provide clinicians and healthcare systems with increasingly integrated and automated solutions
News | Radiology Business
GE HealthCare Closes MIM Software Acquisition

April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc., GE HealthCare ...

Time April 02, 2024
arrow
During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.
News | Molecular Imaging
Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
Lumicell announced the Medical Imaging Drugs Advisory Committee (MIDAC) of the U.S Food and Drug Administration (FDA) voted in support of the benefit-risk profile of LUMISIGHT
News | Breast Imaging
Lumicell Announces FDA Advisory Committee’s Positive Recommendation on the Benefit-Risk Profile of LUMISIGHT in the Detection of Cancerous Tissue During Breast Conserving Surgery

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
Proscia, a software company accelerating the transformation to digital pathology, has announced its receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Concentriq AP-Dx for the purpose of primary diagnosis.
News | FDA
Proscia Receives FDA Clearance for Digital Pathology Software Solution

February 12, 2024 — Proscia, a leading provider of digital and computational pathology solutions, has received 510(k) ...

Time February 12, 2024
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Mid-Winter Conference drew global experts exchanging the latest innovations in diagnostic and molecular imaging, cancer therapies, clinical trials and theranostics, as well and the role of artificial intelligence (AI) in nuclear medicine during its Feb. 1-3, 2024 meeting in Orlando, FL.
News | SNMMI
Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Conference Focuses on Theranostics, AI, Diagnostic Imaging Innovations and Clinical Trials

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
With its latest evolution, Guerbet reports that it offers advanced performance features to its Optistar Elite.
Feature | Contrast Media Injectors | By Christine Book
Market Analysis: Vendor Focus on Optimizing Patient Safety and Radiology Workflow Drives Growth

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Radiology Business
Merger Announced by 4D Medical and Imbio Creates Cardiothoracic Image Analysis Portfolio

December 13, 2023 — The global medical technology company 4DMedical has announced it has entered a binding agreement to ...

Time December 13, 2023
arrow
Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway (gadopiclenol) in the European Union
News | Contrast Media
The European Commission Grants Marketing Authorization to Bracco Imaging for Vueway (gadopiclenol) Contrast Agent in the European Union

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now